Neuroblastoma is a rare childhood tumor that arises from immature sympathetic neurons. In diagnosis, patients are assigned to a specific risk, a classification based on a combination of specific clinical and biological parameters am so for each patient to establish the most appropriate treatment protocol. Follow-up studies have shown that the current classification can lead to over- or under-treatment, so that am optimize the system further requires additional markers. In this context, was performed at the Center for Medical Genetics Ghent research into the identification of prognostic DNA methylation biomarkers. To this end, studies were designed to assess the DNA methylation profiles of neuroblastoma tumors on a genome-wide manner to map out with the aid of methyl-CpG binding domain (MBD) -sequenering, and became a methylation-specific PCR (MSP) technology ge " implemented -amide ge " identified candidate markers for further evaluation. These studies led to the identification of several individual new DNA methylation markers, as well as a robust multi prognostic marker signature. However, the generated MBD-sequeneringsdata may also be of interest to the biological processes that lie at the basis of the tumor pathology, to further elucidate. For this reason it is important that this unique data to be made available to other researchers and thus can also be used for other (more biologically oriented) purposes. To the value of the MBD-sequeneringsdata herein to further illustrate the impact of certain specific biological parameters will be (i.e., the amplificatiestatus of the MYCN oncogene and tumor stage) can be verified on the methylome. Finally, a new technique, called digital droplet MSP, optimized, which should allow to detect DNA methylation in blood from the patient. In this way, the ge " can; biomarkers identified to be translated into a clinically useful assay.